Health Status After Transcatheter Mitral-Valve Repair in Heart Failure and Secondary Mitral Regurgitation
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Background In the COAPT trial, transcatheter mitral valve repair (TMVr) with the edge-to-edge device led to reduced heart failure (HF) hospitalizations and improved survival in patients with symptomatic HF and 3-4+ secondary mitral regurgitation (MR) on maximally-tolerated medical therapy. Given the advanced age and comorbidities of these patients, improvement in health status is also an important treatment goal. Objective To understand the health status outcomes of patients with HF and 3-4+ secondary MR treated with TMVr versus standard care. Methods The COAPT trial randomized patients with HF and 3-4+ secondary MR to TMVr (n=302) or standard care (n=312). Health status was assessed at baseline and at 1, 6, 12, and 24 months with the Kansas City Cardiomyopathy Questionnaire (KCCQ) and the SF-36 health status survey. The primary health status endpoint was the KCCQ overall summary score (KCCQ-OS; range 0-100; higher=better; minimum clinically important difference=5 points). Results At baseline, patients had substantially impaired health status (mean KCCQ-OS 52.4 ± 23.0). While health status was unchanged over time in the standard care arm, patients randomized to TMVr demonstrated substantial improvement in the KCCQ-OS at 1 month (mean between-group difference 15.9 points, 95% CI 12.3 to 19.5) with only slight attenuation of this benefit through 24 months (mean between-group difference 12.8 points, 95% CI 7.5 to 18.2). At 24 months, 36.4% of TMVr patients were alive with a moderately large (≥10-point) improvement vs. 16.6% of standard care patients (p<0.001), for a number needed to treat of 5.1 patients (95% CI 3.6 to 8.7). TMVr patients also reported better generic health status at each timepoint (24-month mean difference in SF-36 summary scores: physical 3.6 points, 95% CI 1.4-5.8; mental 3.6 points, 95% CI 0.8-6.4). Conclusion Among patients with symptomatic HF and 3-4+ secondary MR receiving maximally-tolerated medical therapy, TMVr with the edge-to-edge device resulted in substantial early and sustained health status improvement compared with medical therapy alone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Transcatheter Mitral-Valve Repair in Patients with Heart Failure
Stone, G. W., Lindenfeld, J., Abraham, W. T., Kar, S., Lim, D. S., Mishell, J. M., Whisenant, B., Grayburn, P. A., Rinaldi, M., Kapadia, S. R., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1806640 · Cited by 3,017
Self-citationGreen, C. P., Porter, C. B., Bresnahan, D. R., & Spertus, J. A. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00531-3 · Cited by 1,827
Self-citationPreferences for quality of life or survival expressed by patients with heart failure
Lewis, E. F., Johnson, P. A., Johnson, W., Collins, C., Griffin, L., & Stevenson, L. W. (2001) · The Journal of Heart and Lung Transplantation · doi:10.1016/s1053-2498(01)00298-4 · Cited by 433
Changing preferences for survival after hospitalization with advanced heart failure
Stevenson, L. W., Hellkamp, A. S., Leier, C. V., Sopko, G., Koelling, T., Warnica, J. W., Abraham, W. T., Kasper, E. K., Rogers, J. G., Califf, R. M., et al. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.08.028 · Cited by 164
Self-citation
Cited by
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001063 · Cited by 4,922
Otto, C. M., Nishimura, R. A., Bonow, R. O., Carabello, B. A., Erwin, J. P., Gentile, F., Jneid, H., Krieger, E. V., Mack, M., McLeod, C., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000923 · Cited by 3,686
Self-citation2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.012 · Cited by 2,862
Otto, C. M., Nishimura, R. A., Bonow, R. O., Carabello, B. A., Erwin, J. P., Gentile, F., Jneid, H., Krieger, E. V., Mack, M., McLeod, C., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000932 · Cited by 2,449
Self-citation2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease
Otto, C. M., Nishimura, R. A., Bonow, R. O., Carabello, B. A., Erwin, J. P., Gentile, F., Jneid, H., Krieger, E. V., Mack, M., McLeod, C., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.11.018 · Cited by 1,982
Self-citation2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary
Otto, C. M., Nishimura, R. A., Bonow, R. O., Carabello, B. A., Erwin, J. P., Gentile, F., Jneid, H., Krieger, E. V., Mack, M., McLeod, C., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.11.035 · Cited by 1,075
Self-citation2020 ACC/AHA guideline for the management of patients with valvular heart disease
Otto, C. M., Nishimura, R. A., Bonow, R. O., Carabello, B. A., Erwin, J. P., Gentile, F., Jneid, H., Krieger, E. V., Mack, M., McLeod, C., et al. (2021) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2021.04.002 · Cited by 279
Self-citationButler, J., Filippatos, G., Jamal Siddiqi, T., Brueckmann, M., Böhm, M., Chopra, V. K., Pedro Ferreira, J., Januzzi, J. L., Kaul, S., Piña, I. L., et al. (2022) · Circulation · doi:10.1161/circulationaha.121.057812 · Cited by 206
Chronological vs Biological Age in Interventional Cardiology
Damluji, A. A., Nanna, M. G., Rymer, J., Kochar, A., Lowenstern, A., Baron, S. J., Narins, C. R., & Alkhouli, M. (2024) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2024.01.284 · Cited by 53
Self-citation
Metadata
- Authors
- Arnold, S. V., Chinnakondepalli, K. M., Spertus, J. A., Magnuson, E. A., Baron, S. J., Kar, S., Lim, D. S., Mishell, J. M., Abraham, W. T., Lindenfeld, J. A., Mack, M. J., Stone, G. W., & Cohen, D. J.
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2019-05
- Volume
- 73
- Issue
- 17
- Pages
- 2123-2132
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W2921848961
- Cited by
- 130
- References
- 4
- FWCI
- 12.06
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.